Hongxia Cheng results 57
· Newest (Page 1/3, per page 25)
Author: Hongxia Cheng ×Clear All Filters
Search Results
Model-informed Drug Development (MIDD) Approach to Support Biopharmaceutical Development of IberdomideNARA Subscribed
Iberdomide is a BCS III CELMoD™ agent currently under development for treatment of multiple myeloma. Five formulations were used during clinical development, starting with active ingredient in gelatin capsule (AIC), followed by subsequent formulations in gelatin (F1), HPMC capsules (F2 and F3), and finally the intended commercial form (ICF). A food effect study with the Phase I AIC formulation showed no food effect and two rel...